For a block buster Anti-Cancer Drug
Venus Remedies announced that the Company has entered into a collaborative agreement with TEVA for a block buster Anti-Cancer Drug. This high potential drug is under patent protection till 2016 and is widely used for treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer having a market of more than $4 billion and estimated to increase to $5.4 billion by 2020 in the regulated markets of United States, France, Germany, Italy, Spain, the United Kingdom and Japan.The Company is already in association with TEVA for two Cephalosporins product business from EU market.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app